Bylined article by New York Litigation partner Henninger Bullock and associate Andrew Calica discusses the ruling in Smith v. Wyeth Inc. that brand manufacturers of Reglan could not be held liable for injuries caused by their competitors’ generic versions of the drug.

Downloads –